Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe

References

• European Medicines Agency (EMA): Orphan drugs and rare diseases at a glance. 2007 [ cited 2016 Jul 13]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/01/WC500069805.pdf
   Google Scholar
• NICE. Citizens Council Report Ultra Orphan Drugs; 2004 [ cited 2016 Jul 14]. Available from: https://www.nice.org.uk/Media/Default/Get-involved/Citizens-Council/Reports/CCReport04UltraOrphanDrugs.pdf
   Google Scholar
• Hughes-Wilson W, Palma A, Schuurman A, et al. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012;7:1. [ cited 2016 Jul]. Available from: http://www.ojrd.com/content/7/1/74
   Web of Science ®Google Scholar
• European Commission: Regulation (EC) No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities L18/1-L18/5 (2000). [ cited 2016 Jul] Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF
   Google Scholar
• European Commision Orphan Medicinal Products. [ cited 2016 Jul 13]. Available from: http://ec.europa.eu/health/human-use/orphan-medicines/index_en.htm
   Google Scholar
• EMA Annual Report 2015. [ cited 2016 Sep 13]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Annual_report/2016/05/WC500206482.pdf
   Google Scholar
• Schey C, Milanova T, Hutchings A., et al. Estimating the budget impact of orphan medicines in Europe: 2010-2020. Orphanet J Rare Dis. 2011;6:62.
   Web of Science ®Google Scholar
• Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42.
   PubMed Web of Science ®Google Scholar
• Drummond M, Towse A. Orpan drug policies: a suitable case for treatment. Eur J Health Econ. 2014;15:335–16.
   PubMed Web of Science ®Google Scholar
• Cote A, Keating B. What is wrong with orphan drug policies? Value Health. 2012;15:1185–1191.
   PubMed Web of Science ®Google Scholar
• Simoens S, Cassiman D, Dooms M, et al. Orphan drugs for rare diseases: is it time to revisit their special market access status? Drugs. 2012;72(11):1437–1443.
   PubMed Web of Science ®Google Scholar
• Michel M, Toumi M. Access to orphan drugs in Europe: current and future issues. Expert Rev Pharmacoecon Outcomes Res. 2012;12(1):23–29.
   PubMed Web of Science ®Google Scholar
• Picavet E, Dooms M, Cassiman D, et al. Drugs for rare diseases: influenceof orphan designation status on price. Appl Health Econ Health Policy. 2011;9(4):275–279.
   PubMedGoogle Scholar
• Picavet E, Morel T, Cassiman D, et al. Shining a light in the black box of orphan drug pricing. Orphanet J Rare Dis. 2014;9:62.
   PubMed Web of Science ®Google Scholar
• Drummond M, Wilson DA, Kanavos P, et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23(1):36–42.
   PubMed Web of Science ®Google Scholar
• Le Cam Y. Inventory of access and prices of orphan drugs across Europe: a collaborative work between national alliances on rare diseases & EURODIS. Paris, France: EURODIS; 2010.
   Google Scholar
• Heemstra HE. Variations in access and use of orphan drugs among EU member states. Eur J Hosp Pharm Practice. 2010;15(4):25–27.
   Google Scholar
• Denis A, Mergaert L, Fostier C, et al. A comparative study of European rare disease and orphan drug markets. Health Policy. 2010;97:173–179.
   PubMed Web of Science ®Google Scholar
• Gammie T, Lu CY, Babar ZU-D, et al. Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. Plos One. 2015;10(10):e0140002.
   PubMed Web of Science ®Google Scholar
• Toumi M, Rémuzat C, Vataire AL, et al. External reference pricing of medicinal products: simulation based considerations for crosscountry coordination; 2013 [ cited 2016 Jul]. Available from: http://ec.europa.eu/health/healthcare/docs/erp_reimbursement_medicinal_products_en.pdf
   Google Scholar
• Schlander M, Holm S, Nord E, et al. Towards Social Cost Value Analyis: the Need for New Approaches for Evaluating Drugs for Ultra-Rare Disorders (Urds). Institute for Innovation and Valuation in Health Care; 2015 [cited 2016 Jul]. Available from: http://www.innoval-hc.com/discussion-papers.html
   Google Scholar
• Desser A, Gyrd-Hansen D, Olsen JA, et al. Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67. BMJ. 2010;341:c4715.
   Google Scholar
• McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ. 2005;331:1016–1019.
   PubMed Web of Science ®Google Scholar
• Gutierrez L, Patris J, Hutchings A, et al. Principles for consistent value assessment and sustainable funding of orphan drugs in Europe. Orphanet J Rare Dis. 2015;10:53.
   Web of Science ®Google Scholar
• Sussex J, Rollet P, Garau M, et al. A pilot study of multicriteria decision analysis for valuing orphan medicines. Value Health. 2013;16:1163–1169.
   PubMed Web of Science ®Google Scholar
• Paulden M, Stafinski T, Menon D, et al. Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework. PharmacoEconomics. 2015;33:255–269.
   PubMed Web of Science ®Google Scholar
• Wagner M, Khoury H, Willet J, et al. Can the EVIDEM framework tackle issues raised by evaluating treatments for rare diseases: analysis of issues and policies, and context-specific adaptation. PharmacoEconomics. 2016;34:285–301.
   PubMed Web of Science ®Google Scholar
• Palaska C, Hutchings A. Value assessment and pricing frameworks for rare disease treatments: new approaches from the literature. In: ISPOR 18th Annual European Congress; 2015 Nov; Milan, Italy. [cited 2016 Jul]. Available from: http://www.ispor.org/research_pdfs/51/pdffiles/PSY113.pdf
   Google Scholar
• Fellows GK, Hollis A. Funding innovation for treatment for rare diseases: adoptinga cost-based yardstick approach. Orphanet J Rare Dis. 2013;8:180.
   PubMed Web of Science ®Google Scholar
• IHS PharmOnline International (POLI). [ cited 2016 Jul]. Available from: https://www.ihs.com/products/pharmaonline-international.html
   Google Scholar
• Ameli. [ cited 2016 Jul]. Available from: http://www.codage.ext.cnamts.fr/codif/bdm_it/index.php?p_site=AMELI
   Google Scholar
• The British National Formulary (BNF). [ cited 2016 Jul]. Available from: https://www.medicinescomplete.com/mc/login.htm
   Google Scholar
• Farmadati. [ cited 2016 Jul]. Available from: http://www.farmadati.it/
   Google Scholar
• WHO. Child Growth Standards: Weight for Age. [ cited 2016 Jul]. Available from: http://www.who.int/childgrowth/standards/weight_for_age/en/
   Google Scholar
• European Medicines Agency. Rare disease (orphan) designations; [ cited 2016 Jul]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Forphan_search.jsp&mid=WC0b01ac058001d12b&searchkwByEnter=false&alreadyLoaded=true&isNewQuery=true&status=Positive&status=Negative&status=Withdrawn&status=Expired&startLetter=A&keyword=Enter+keywords&searchType=Active+Substance
   Google Scholar
• Alcimed. Study on orphan drugs. Paris. 2005 [ cited 2016 Jul]. Available from: http://ec.europa.eu/health/files/orphanmp/doc/pricestudy/final_final_report_part_1_web_en.pdf
   Google Scholar
• Messori A, Cicchetti A, Patregani L. Orphan drugs: relating price determination to disease prevalence. BMJ. 2010;341:c4615.
   PubMed Web of Science ®Google Scholar
• Aballea S, Toumi M, Vataire AL, et al. Quantitative analysis of the influence of disease and product characteristics on orphan drug prices in Europe. In: ISPOR 15th Annual International Meeting; 2010 May 15–19; Atlanta, GA. [cited 2016 Jul]. Available from: http://www.creativ-ceutical.com/sites/default/files/ISPOR%20International_Creativ-Ceutical_Orphan%20Drugs%20Poster.pdf
   Google Scholar
• Onakpoya I, Spencer EA, Thompson MJ, et al. Effectiveness, safety and costs of orphan drugs: an evidence-based review. BMJ Open. 2015;5:e007199.
   PubMed Web of Science ®Google Scholar
• EMA. Public statement on Onsenal (celecoxib). 2011 Apr [cited 2016 Jul]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2011/04/WC500104950.pdf
   Google Scholar
• Rémuzat C, Toumi M, Falissard B. New drug regulations in France: what are the impacts on market access? Part 1 - overview of new drug regulations in France. J Market Access Health Policy 2013;1:20891.
   Google Scholar